{"text": "Assessment of Pain by the Participant Using Visual Analog Scale ( VAS )[ Time Frame : Baseline and Weeks 4 , 8 , 12 , 16 , 20 , 24 , 36 , 48 and 52 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "44.04513"}
{"text": "Assessment of Global Disease by the Physician Using Visual Analog Scale ( VAS )[ Time Frame : Baseline and Weeks 4 , 8 , 12 , 16 , 20 , 24 , 36 , 48 and 52 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "44.446896"}
{"text": "Visual analog scale ( VAS ) scores for back pain and leg pain and Oswestry Disability Index ( ODI ) sores were recorded preoperatively , and at 3 , 6 , and 12 months postoperatively .", "label": "", "metadata": {}, "score": "48.088688"}
{"text": "Visual analog scale ( VAS ) scores for back pain and leg pain and Oswestry Disability Index ( ODI ) sores were recorded preoperatively , and at 3 , 6 , and 12 months postoperatively .", "label": "", "metadata": {}, "score": "48.088688"}
{"text": "Assessment of Global Disease by the Participant Using VAS [ Time Frame : Baseline and Weeks 4 , 8 , 12 , 16 , 20 , 24 , 36 , 48 and 52 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "49.20412"}
{"text": "Children showing VAS after completing the injection ? 7 Data presented as mean?SD or n of patients ( % ) .aMann - Whitney U - test was used to compare pain scores ; ? 2-test was used to compare categorical data between the two groups .", "label": "", "metadata": {}, "score": "50.244614"}
{"text": "The Fibromyalgia Impact Questionnaire includes a pain visual analog scale ( VAS ) with ranges of 0 - 10 centimeters .Higher values represent greater pain .", "label": "", "metadata": {}, "score": "51.068703"}
{"text": "The Fibromyalgia Impact Questionnaire includes a sleep visual analog scale ( VAS ) with ranges of 0 - 10 centimeters .Higher values represent greater difficulty with sleep .", "label": "", "metadata": {}, "score": "51.875034"}
{"text": "Correlations between changes across various PRO instruments were explored .Results .Conclusions .Apremilast treatment resulted in improved HRQOL , including DLQI and pruritus VAS over 16 weeks of treatment , in patients with moderate to severe psoriasis .", "label": "", "metadata": {}, "score": "52.64067"}
{"text": "In the maintenance phase , corticosteroid ointments were discontinued and tacrolimus ointment was applied twice daily for an additional 2 week period .The EASI score , severity of pruritus , and sleep disturbance scores , as well as QOL evaluations by DLQI and SF-36 were measured .", "label": "", "metadata": {}, "score": "52.997276"}
{"text": "Number of Participants Who Had Measurable Pruritis Based on a Visual Horizontal Analog Scale [ Time Frame : Baseline through Study Day 36 ( Visit 7 ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "53.694824"}
{"text": "Eligible children were randomly assigned to receive either EMLA \u00ae or placebo cream .The Modified Behavioural Pain Scale ( MBPS ) was used to assess baseline and postvaccination pain scores , while a visual analogue scale ( VAS ) was used to assess pain at the time of the needle prick and at the end of the injection .", "label": "", "metadata": {}, "score": "54.096344"}
{"text": "Eligible children were randomly assigned to receive either EMLA?or placebo cream .The Modified Behavioural Pain Scale ( MBPS ) was used to assess baseline and postvaccination pain scores , while a visual analogue scale ( VAS ) was used to assess pain at the time of the needle prick and at the end of the injection .", "label": "", "metadata": {}, "score": "55.946857"}
{"text": "SHAQ - DI assessed five scleroderma - specific visual analogue scale ( VAS ) items to explore the impact of participant 's disease .These items were developed to measure the effect of scleroderma on five elements of disease that could have a great impact on a participant 's daily activities .", "label": "", "metadata": {}, "score": "56.00865"}
{"text": "As a benchmark comparison , US normative data were calculated based on age and gender distribution of the protocol population [ 32 ] .Pearson correlations ( r ) were determined for mean changes from baseline between the generic SF-36 Bodily Pain ( BP ) and Vitality ( VT ) domains and MCS scores at week 16 with disease - specific DLQI and pruritus VAS scores .", "label": "", "metadata": {}, "score": "56.348732"}
{"text": "The smaller the number the better the patient feels .The results are the difference of the SKINDEX scoring scale at treatment discharge ( day 22 ) minus baseline ( day-7 ) .", "label": "", "metadata": {}, "score": "56.356876"}
{"text": "An electronic Visual Analog Scale ( eVAS ) was used by the subject to assess ocular discomfort , both frequency and severity , at Day 0 ( pre - treatment ) and daily thereafter for 28 days .", "label": "", "metadata": {}, "score": "56.60339"}
{"text": "Percentage of Responders Using the Global Response Assessment ( GRA )[ Time Frame : Baseline , Days 7 , 14 , 28 and 42 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "57.4461"}
{"text": "Recently , topline results from the ESTEEM 1 trial were presented [ 39 ] .Apremilast was also associated with significant improvements in static Physician 's Global Assessment , pruritus VAS , and DLQI as well as difficult - to - treat nail and scalp psoriasis .", "label": "", "metadata": {}, "score": "58.171215"}
{"text": "Results : VAS scores for back pain and leg pain and ODI revealed statistically significant improvement when they were compared with preoperative values .Mean hospital stay was statistically shorter in the LA group .", "label": "", "metadata": {}, "score": "58.893295"}
{"text": "Results : VAS scores for back pain and leg pain and ODI revealed statistically significant improvement when they were compared with preoperative values .Mean hospital stay was statistically shorter in the LA group .", "label": "", "metadata": {}, "score": "58.893295"}
{"text": "On this scale , a numerical increase indicated an improvement in the participant 's condition .Change From Baseline in 5-D Itch Scale at Week 24 and Week 48 [ Time Frame : Baseline , Weeks 24 and 48 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "58.952557"}
{"text": "Discussion .Statistically significant and clinically meaningful improvements in SF-36 MCS and domain scores were reported by patients treated with apremilast , most evident in the 20- and 30-mg BID dose groups , mirrored by decreases in disease - specific DLQI and pruritus VAS scores .", "label": "", "metadata": {}, "score": "59.138393"}
{"text": "An increase in score indicates improvement .MCID , minimal clinically important difference ; SF-36 , 36-item Short - Form Health Survey .Correlations among DLQI , pruritus VAS , and SF-36 scores .", "label": "", "metadata": {}, "score": "59.343613"}
{"text": "Table 4 .Correlations of changes in SF-36 BP , VT , and MCS scores with changes in DLQI and pruritus VAS scores at week 16 .", "label": "", "metadata": {}, "score": "59.609272"}
{"text": "Taddio A , O'Brien L , Ipp M , et al .Reliability and validity of observer ratings of pain using the visual analog scale ( VAS ) in infants undergoing immunization injections .", "label": "", "metadata": {}, "score": "59.637615"}
{"text": "Reductions in baseline PASI scores were evident by week 2 , with a separation across doses observed by weeks 2 to 4 ; improvements were maintained over 24 weeks ' treatment .", "label": "", "metadata": {}, "score": "59.88237"}
{"text": "A score of 2 ( Moderate Pruritus ) , 3 ( Severe Pruritus ) or 4 ( Very Severe Pruritus ) on the Five - Point Pruritus Scale .", "label": "", "metadata": {}, "score": "59.94323"}
{"text": "A negative change from Baseline indicates improvement .Change From Baseline in Participant Reported Bladder Pain as Assessed by a Visual Analog Scale ( VAS ) at Day 14 [ Time Frame : Baseline , Day 14 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "59.954597"}
{"text": "Correlations between SF-36 MCS , BP , and VT scores and DLQI were moderate and , in general , statistically significant .Correlations between SF-36 scores and pruritus VAS were moderate to low , indicating that they measure different impacts of the disease and highlighting the value in assessing efficacy using multiple instruments .", "label": "", "metadata": {}, "score": "60.24469"}
{"text": "Week 16 mean changes from baseline in PCS scores were numerically greater with apremilast 10 , 20 , and 30 mg BID than placebo but were neither statistically significantly nor clinically meaningful .", "label": "", "metadata": {}, "score": "60.307274"}
{"text": "At 12 months after surgery , the mean VAS for back pain was 10.54 ( range , 0 - 20 ) , the mean VAS for leg pain was 11.11 ( range , 0 - 30 ) , and mean ODI was 9.13 ( range , 0 - 22 ) [ Figures 3 - 5].", "label": "", "metadata": {}, "score": "60.542984"}
{"text": "A negative change from Baseline indicates improvement .Change From Baseline in Interstitial Cystitis Problem Index ( ICPI )Score [ Time Frame : Baseline , Days 7 , 14 , 28 and 42 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "60.673485"}
{"text": "The VAS frequency score ranged from 0 ( rarely ) to 100 ( all the time ) , and the VAS severity score ranged from 0 ( very mildly uncomfortable ) to 100 ( very severely uncomfortable ) .", "label": "", "metadata": {}, "score": "60.762096"}
{"text": "PROs were evaluated based on the intent - to - treat population using last - observation - carried - forward ( LOCF ) to account for missing values .", "label": "", "metadata": {}, "score": "60.86104"}
{"text": "Week 16 percent change from baseline in mean pruritus VAS scores was compared using the Wilcoxon test for each apremilast group versus placebo .If either PCS and/or MCS scores of SF-36 were statistically significant , significance was tested for the individual domain scores , without P value corrections for multiplicity .", "label": "", "metadata": {}, "score": "61.16581"}
{"text": "The mRSS was rated with scores ranging from 0 ( normal ) to 3 ( severe skin thickening ) across 17 different sites .A negative change from baseline showed improvement .", "label": "", "metadata": {}, "score": "61.328156"}
{"text": "Pain was considered to be severe at scores ?The reliability and validity of the VAS and MBPS in evaluating pain associated with vaccinations have previously been con-", "label": "", "metadata": {}, "score": "61.34969"}
{"text": "Pain scale measurements EMLA?group n\u00bc107 3.36 ? 2.27 9 ( 8.4 ) 2 ( 1.9 ) 12 ( 11.2 ) Placebo group n\u00bc109 3.37 ? 2.20 25 ( 22.9 ) 11 ( 10.1 ) 38 ( 34.6 ) Statistical significancea MBPS , baseline MBPS , 0 - 10s after injection MBPS difference between baseline and after injection VAS at the beginning of the injection VAS after completing the injection Children showing MBPS score difference ? 7", "label": "", "metadata": {}, "score": "61.449272"}
{"text": "The difference between the pre- and postvaccination MBPS scores was significantly lower in the EMLA group than in the placebo group ( 2.56 ? 1.96 versus 3.95 ? 2.20 , respectively ) .", "label": "", "metadata": {}, "score": "61.705338"}
{"text": "EASI scores and the pruritus and sleep disturbance scores decreased by 2 weeks , and continued improvement was observed throughout the study .On SF-36 and DLQI surveys , the mean QOL scores improved after completion of therapy at week 6 .", "label": "", "metadata": {}, "score": "61.872444"}
{"text": "There were no statistically significant differences in VAS or ODI scores between the LA and GA groups .The mean operative time in the LA group was 67.07 min ( range , 25 - 140 ) , and in the GA group was 74.78 min ( range , 50 - 130 ) , but this difference was not statistically significant .", "label": "", "metadata": {}, "score": "61.998634"}
{"text": "The difference between the pre- and postvaccination MBPS scores was significantly lower in the EMLA group than in the placebo group ( 2.56 \u00b1 1.96 versus 3.95 \u00b1 2.20 , respectively ) .", "label": "", "metadata": {}, "score": "62.037582"}
{"text": "Change From Baseline in Participant Reported Bladder Pain as Assessed by a Visual Analog Scale ( VAS ) at Day 42 [ Time Frame : Baseline , Day 42 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "62.364594"}
{"text": "While the most commonly reported adverse events were related to gastrointestinal complaints and headache , this did not appear to outweigh the benefit of therapy , and resulted in an overall improvement in HRQOL .", "label": "", "metadata": {}, "score": "62.505688"}
{"text": "The severity of skin lesions and itching measured by VAS also decreased significantly .Neither local irritation nor abnormal changes in serum calcium levels were noted .", "label": "", "metadata": {}, "score": "62.709366"}
{"text": "Change From Baseline in Participant Reported Bladder Pain as Assessed by a Visual Analog Scale ( VAS ) ay Day 28 [ Time Frame : Baseline , Day 28 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "63.067024"}
{"text": "Measures were completed at hospital discharge and at 6 , 12 , and 24 months after injury .Spearman 's correlations were used to examine the correlation between itch intensity and associated symptoms .", "label": "", "metadata": {}, "score": "63.147255"}
{"text": "Annual Meeting of the American Academy of Dermatology ; 2013 .Copyright .\u00a9 Strand et al . ; licensee BioMed Central Ltd. 2013 .This article is published under license to BioMed Central Ltd. Bottom Line : Results were compared to evaluate the technique feasibility , safety , and efficacy under LA and GA.VAS scores for back pain and leg pain and ODI revealed statistically significant improvement when they were compared with preoperative values .", "label": "", "metadata": {}, "score": "63.491665"}
{"text": "Subjects will complete the Five - Point Pruritus Scale once at Screening ( Visit 1 ) , then twice daily beginning at baseline , which occurs on the morning of Study Day -7 ( Visit 2 ) , through Study Day 36 ( Visit 7 ) .", "label": "", "metadata": {}, "score": "63.678246"}
{"text": "DLQI .Values are mean \u00b1 SD .DLQI , Dermatology Life Quality Index ; VAS , visual analog scale .Pruritus VAS .Baseline pruritus VAS scores were well matched across treatment groups ( Table 3 ) .", "label": "", "metadata": {}, "score": "63.918655"}
{"text": "Participants reported symptom of urinary urgency in the last 24 hours using a Urgency Visual Analogue Scale ( VAS ) .Participants were instructed to complete the Pain VAS by marking the spot on the line that corresponded to their urinary urgency .", "label": "", "metadata": {}, "score": "63.924686"}
{"text": "Assessment of Physical Function Using Health Assessment Questionnaire ( HAQ )[ Time Frame : Baseline and Weeks 4 , 8 , 12 , 16 , 20 , 24 , 36 , 48 and 52 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "63.98214"}
{"text": "Change in pruritus is assessed twice daily beginning at baseline , Study Day -7 ( Visit 2 ) , through Study Day 36 ( Visit 7 ) .", "label": "", "metadata": {}, "score": "64.11977"}
{"text": "Change in Number of Positive Tender Points [ Time Frame : Total timeframe 13 weeks : baseline followed by 11 weeks of treatment with outcome assessed within 14 days following end of treatment ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "64.34907"}
{"text": "EMLA ?1.88 Application time , min 3.37 ?16.15 Data presented as mean?SD or n of patients ( % ) .No statistically significant between - group differences ( P ? 0.05 ) ; Student 's t - test was used to compare con- tinuous data , Mann - Whitney U - test was used to compare pain scores and ? 2-test was used to compare categorical data 332Journal of International Medical Research 42(2 ) .", "label": "", "metadata": {}, "score": "64.39961"}
{"text": "10.2165/00128071 - 200506060 - 00005 PubMed View Article .Reich A , Hrehorow E , Szepietowski JC : Pruritus is an important factor negatively influencing the well - being of psoriatic patients .", "label": "", "metadata": {}, "score": "64.60054"}
{"text": "Data are expressed as mean ?SD , n of patients ( % ) or median ( interquar- tile range ) .Student 's t - test was used to compare continuous data , Mann - Whitney U - test was used to compare pain scores ( ordinal data ) , and ? 2-test was used to compare categorical data .", "label": "", "metadata": {}, "score": "64.62686"}
{"text": "Both the MBPS score recorded by the observer and the VAS score recorded by the nurse administering the vaccines correlated well to support the effectiveness of EMLA?in pain relief .", "label": "", "metadata": {}, "score": "64.9507"}
{"text": "Page 6 . the child arrived in the Well - baby Paediatric Clinic until they received their first vaccine injection was 57.08 ?16.65min for the total study population , which was an adequate application time for EMLA ?", "label": "", "metadata": {}, "score": "65.20005"}
{"text": "Percentage of Participants With Treatment - Emergent Adverse Events ( AEs ) and Serious Adverse Events ( SAEs )[ Time Frame : Week 48 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "65.947586"}
{"text": "Skin symptoms were assessed using the score of the modified psoriasis area and severity index ( PASI ) scoring system , which excludes assessment of the face and head from the PASI scoring system , and a visual analog scale ( VAS ) score reported by the subjects .", "label": "", "metadata": {}, "score": "65.95768"}
{"text": "The mean preoperative VAS score for back pain was 57.65 ( range , 0 - 100 ) and for leg pain was 75.88 ( range , 10 - 100 ) , and the mean preoperative ODI was 48.49 ( range , 14 - 84 ) .", "label": "", "metadata": {}, "score": "66.15564"}
{"text": "From Week 49 to Week 96 , all patients will receive open - label RoActemra/ Actemra 162 mg subcutaneously weekly .Anticipated time on study treatment is 96 weeks .", "label": "", "metadata": {}, "score": "66.291855"}
{"text": "Disease - associated decrements in HRQOL reported by patients with psoriasis indicate that a multipronged approach could enhance assessment of treatment effectiveness .This approach should encompass clinical signs and symptoms , as well as patient - reported HRQOL , using both disease - specific and generic instruments .", "label": "", "metadata": {}, "score": "66.31402"}
{"text": "View Article .Krueger GG , Langley RG , Finlay AY , Griffiths CE , Woolley JM , Lalla D , Jahreis A : Patient - reported outcomes of psoriasis improvement with etanercept therapy : results of a randomized phase III trial .", "label": "", "metadata": {}, "score": "66.37793"}
{"text": "Across all three active doses , statistically significant improvements were reported in BP , MH , and RE , and in SF for apremilast 20 and 30 mg BID , contributing to statistically significant changes in MCS scores .", "label": "", "metadata": {}, "score": "66.499016"}
{"text": "In this 16-week , placebo - controlled study , 352 patients with moderate to severe plaque psoriasis received placebo or apremilast ( 10 , 20 , or 30 mg BID ) .", "label": "", "metadata": {}, "score": "66.50036"}
{"text": "Change From Baseline in Patient 's Global Assessment at Week 24 and Week 48 [ Time Frame : Baseline , Weeks 24 and 48 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "66.67113"}
{"text": "Time To Achieve ACR20/ACR50/ACR70 [ Time Frame : Weeks 4 , 8 , 12 , 16 , 20 , 24 , 36 , 48 and 52 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "66.932205"}
{"text": "Percentage of Participants Achieving Remission Assessed Using DAS28[ Time Frame : Baseline and Weeks 4 , 8 , 12 , 16 , 20 , 24 , 36 , 48 and 52 ] [ Designated as safety issue : No ] . DAS28", "label": "", "metadata": {}, "score": "66.96007"}
{"text": "Percentage of Participants With Anti - Tocilizumab Antibody [ Time Frame : Baseline , and post - baseline ( up to Week 48 ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "67.0096"}
{"text": "A responder was defined as a participant who rated their symptoms as either Moderately or Markedly improved .Change From Baseline in Urinary Urgency as Assessed by VAS [ Time Frame : Baseline , Days 7 , 14 , 28 and 42 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "67.18328"}
{"text": "Original Primary Outcome Measures ICMJE ( submitted : February 14 , 2012 ) .Change in modified Rodnan skin score ( mRSS ) [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "67.43432"}
{"text": "An increase in score indicates improvement .MCID , minimal clinically important difference ; SF-36 , 36-item Short - Form Health Survey .SF-36 domain scores at baseline and week 16 with apremilast 30 mg BID .", "label": "", "metadata": {}, "score": "67.63571"}
{"text": "Whether a cry occurred was noted and total crying time was measured .Infant pain during the vaccination was also assessed by the nurse administering the vaccine at two stages : at the moment of the needle prick , childrenusingthe PainScale study treatment , child , differences and after finishing the injection and remov- ing the needle .", "label": "", "metadata": {}, "score": "67.66486"}
{"text": "There were 430 pediatric burn survivors with a mean age of 7.8 years and a mean TBSA of 40.8 % .Pruritus is present in most children ( 93 % ) and is of moderate intensity ( 5.7 \u00b1 3.1 ) at discharge .", "label": "", "metadata": {}, "score": "67.79956"}
{"text": "J Rheumatol 2005 , 32 : 590 - 601 .PubMed .Hazes JM , Taylor P , Strand V , Purcaru O , Coteur G , Mease P : Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol .", "label": "", "metadata": {}, "score": "67.90587"}
{"text": "The purpose and ( primary ) objectives of this study are to evaluate the efficacy , safety , and tolerability of TS-022 in adults with atopic dermatitis who have moderate to very severe pruritus ( itching ) , following a 28-day regimen of twice - daily topical application .", "label": "", "metadata": {}, "score": "68.18584"}
{"text": "Percentage of Participants With Change From Baseline in Cystoscopic Examination Findings [ Time Frame : Baseline , Day 14 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "68.20705"}
{"text": "[ Time Frame : Study Day -7 through Study Day 22 ] [ Designated as safety issue : No ] .Assessment of subject 's activities of daily living using the SKINDEX-29 questionnaire to measure the subject 's overall quality of life based on a change in scale from baseline .", "label": "", "metadata": {}, "score": "68.303955"}
{"text": "Results .Patients .Patients had plaque psoriasis for a mean of 19 years and 21 % had PsA ( Table 2 ) .Table 2 .", "label": "", "metadata": {}, "score": "68.52173"}
{"text": "The study enrolled patients with moderate to severe plaque psoriasis and results may not be applicable to patients with other forms of psoriasis .This report is based on PROs after 16 weeks of treatment , although a separate publication indicates that improvements with active therapy are generally maintained over 24 weeks of treatment [ 20 ] .", "label": "", "metadata": {}, "score": "68.74884"}
{"text": "Change From Baseline in Health Assessment Questionnaire - Disability Index ( HAQ - DI ) Score at Week 24 and Week 48 [ Time Frame : Baseline , Weeks 24 and 48 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "68.858894"}
{"text": "It is hypothesized that clinical improvements would be accompanied by improvements in patient - assessed HRQOL .This report summarizes the impact of apremilast on patient - reported outcomes ( PROs ) over the initial 16-week placebo - controlled treatment phase of this trial .", "label": "", "metadata": {}, "score": "69.05348"}
{"text": "HRQOL , health - related quality of life ; MCID , minimum clinically important differences ; MCS , mental component summary ; PCS , physical component summary ; SF-36 , 36-Item Short - Form Health Survey version 2 .", "label": "", "metadata": {}, "score": "69.46687"}
{"text": "Change From Baseline in Tender Joint Count 28 ( TJC28 ) [ Time Frame : Baseline , Weeks 3 , 8 , 16 , 24 , 32 , 40 , and 48 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "69.52852"}
{"text": "Change in Fibromyalgia Impact Questionnaire Overall Score [ Time Frame : Total timeframe 13 weeks : baseline followed by 11 weeks of treatment with outcome assessed within 14 days following end of treatment ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "69.547615"}
{"text": "P values ( vs. placebo ) , based on ANCOVA , with treatment as the factor , and baseline value as the covariate .An increase in score indicates improvement .", "label": "", "metadata": {}, "score": "69.548874"}
{"text": "The only observed adverse event was pallor at the site of cream application , which was seen significantly more frequently in the EMLA?group compared with the placebo group ( 31/107 [ 29.0 % ] versus 5/109 [ 4.6 % ] , respectively ; resolved spontaneously .", "label": "", "metadata": {}, "score": "69.77558"}
{"text": "Data were combined using standardized mean difference ( SMD ) or relative risk ( RR ) with 95 % confidence intervals ( CI ) .Fifty - Five studies that examined breastfeeding ( which combines sweet - tasting solution , holding and sucking ) , topical anesthetics , sweet - tasting solutions ( sucrose , glucose ) , vapocoolants , oral analgesics , and combination of two versus one intervention were included .", "label": "", "metadata": {}, "score": "70.01806"}
{"text": "MCID , minimal clinically important difference ; SF-36 , 36-item Short - Form Health Survey .SF-36 domain scores at baseline and week 16 with apremilast 20 mg BID .", "label": "", "metadata": {}, "score": "70.13725"}
{"text": "The mean?SD application time was 56.52 ?17.14min for the EMLA?group ( range 19 - 103min ) versus 57.64 ?16.15min ( range 32 - 97min ) after the injection forthe placebo Table 1 .", "label": "", "metadata": {}, "score": "70.22239"}
{"text": "Values are mean \u00b1 SD or n ( % ) .BMI , body mass index ; BSA , body surface area ; PASI , Psoriasis Area and Severity Index ; PsA , psoriatic arthritis .", "label": "", "metadata": {}, "score": "70.28757"}
{"text": "Hence subjects can not feel the signal , and are therefore blinded to treatment arm .Investigators and clinical staff are also blinded .Outcome measures include post - treatment to baseline changes in tender points , sleep characteristics as measured by visual analog scales , and outcomes instruments including the Fibromyalgia Impact Questionnaire .", "label": "", "metadata": {}, "score": "70.44801"}
{"text": "Safety assessment of all subjects who received investigational product .Outcome measure is number of subjects with an adverse event .Measures of adverse events in participants included vital signs , laboratory findings , physical exams , electrocardiograms .", "label": "", "metadata": {}, "score": "70.553444"}
{"text": "The mean operative time in the LA group was 67.07 min ( range , 25 - 140 ) , and in the GA group was 74.78 min ( range , 50 - 130 ) , but this difference was not statistically significant .", "label": "", "metadata": {}, "score": "70.62332"}
{"text": "Since 18 tender points are measured on a patient and their individual dolorimeter values summed , the range of tender point pain threshold values is 0 - 72 .", "label": "", "metadata": {}, "score": "70.74853"}
{"text": "Health - related quality of life .LOCF : .Last observation carried forward .MCID : .Minimum clinically important differences .MCS : .", "label": "", "metadata": {}, "score": "70.80754"}
{"text": "Only local pallor at the site of cream application was observed in just under one - third of participants in the EMLA?group .In this present study , the mean?SD total vaccination appointment time from when Table 2 .", "label": "", "metadata": {}, "score": "70.938324"}
{"text": "These included local skin reactions , such as blanching and local ery- thema , which were assessed at the time of dressing removal and 15min later .", "label": "", "metadata": {}, "score": "70.98224"}
{"text": "Whereas the mean?SD for the total vaccination appointment time ( measured from when the child arrived in the Well - baby Paediatric Clinic until they received their first vaccine injection ) was 57.08 ?", "label": "", "metadata": {}, "score": "71.087036"}
{"text": "Despite this , each therapy 's benefit can be compromised by poor tolerability , adverse events , and route of administration ( particularly injection / infusion reactions ) [ 11 , 12 ] .", "label": "", "metadata": {}, "score": "71.11261"}
{"text": "10.1111/j.1524 - 4733.2008.00352.x PubMed View Article .Ara R , Brazier J : Predicting the short form-6D preference - based index using the eight mean short form-36 health dimension scores : estimating preference - based health - related utilities when patient level data are not available .", "label": "", "metadata": {}, "score": "71.14023"}
{"text": "Improvements in patient - reported outcomes with apremilast , an oral phosphodiesterase 4 inhibitor , in the treatment of moderate to severe psoriasis : results from a phase IIb randomized , controlled study .", "label": "", "metadata": {}, "score": "71.21927"}
{"text": "Skin thickness was assessed by the mRSS .The mRSS was rated with scores ranging from 0 ( normal ) to 3 ( severe skin thickening ) across 17 different sites .", "label": "", "metadata": {}, "score": "71.22866"}
{"text": "Skin thickness was assessed by the mRSS .The mRSS was rated with scores ranging from 0 ( normal ) to 3 ( severe skin thickening ) across 17 different sites .", "label": "", "metadata": {}, "score": "71.22866"}
{"text": "The median MBPS difference and the interquartile range , as well as the minimum and maximum values for each vaccine type compared with the overall are presented in Figure 1 .", "label": "", "metadata": {}, "score": "71.25607"}
{"text": "J Invest Dermatol 2005 , 125 : 659 - 664 .10.1111/j.0022 - 202X.2005.23621.x PubMed View Article .Strand V , Crawford B , Singh J , Choy E , Smolen JS , Khanna D : Use of \" spydergrams \" to present and interpret SF-36 health - related quality of life data across rheumatic diseases .", "label": "", "metadata": {}, "score": "71.442116"}
{"text": "Clinical studies have demonstrated the efficacy and tolerability of apremilast in moderate to severe psoriasis and psoriatic arthritis ( PsA ) [ 20 - 22 ] .", "label": "", "metadata": {}, "score": "71.52321"}
{"text": "They first estab- lished a baseline MBPS score for the 10s period that preceded the injection , and rated another MBPS score within 10s after the injection .", "label": "", "metadata": {}, "score": "71.52851"}
{"text": "Although this was an uncontrolled and open - label study , we established that a fixed sequential regimen of 0.1 % tacrolimus ointment with tapering of topical corticosteroids could maintain clinical control of adult AD and improve the QOL .", "label": "", "metadata": {}, "score": "71.652054"}
{"text": "Throughout the trial , concomitant phototherapy and use of systemic and biologic agents were prohibited .Use of topical agents was also prohibited , with the exception of Eucerin \u00ae cream for body lesions ; low - potency corticosteroids for facial , axillary , and groin psoriasis lesions ; and coal tar shampoo or salicylic acid preparations for scalp lesions .", "label": "", "metadata": {}, "score": "71.72844"}
{"text": "Taddio A , Manley J , Potash L , et al .Routine immunization practices : use of topical anes- thetics and oral analgesics .Pediatrics 2007 ; 120 : e637-e643 .", "label": "", "metadata": {}, "score": "71.7613"}
{"text": "The change in Fibromyalgia Impact Questionnaire is determined by subtracting scores at baseline from scores at end of treatment .Thus negative numbers represent symptom improvement ( i.e. a better outcome ) and positive numbers represent symptom worsening ( i.e. a worse outcome ) .", "label": "", "metadata": {}, "score": "71.867004"}
{"text": "Furthermore , the severity of psoriasis symptoms , and pruritus in particular , has been linked to the degree of HRQOL impairment [ 3 , 4 ] .", "label": "", "metadata": {}, "score": "71.93265"}
{"text": "Growing evidence clearly shows that impairments in HRQOL are a large component of the disease burden imposed by psoriasis .These results are in line with national survey findings that show the majority of individuals with psoriasis experience emotional as well as physical disease - related problems [ 34 ] .", "label": "", "metadata": {}, "score": "72.000206"}
{"text": "Visual analog scale .VT : .Vitality .Declarations .Acknowledgements .This study was sponsored by Celgene Corporation .The authors received editorial support in the preparation of this manuscript from Peloton Advantage , LLC , and Jennifer Schwinn , RPh , funded by Celgene Corporation .", "label": "", "metadata": {}, "score": "72.01218"}
{"text": "Findings indicate that the benefit : risk profile of apremilast results in a net improvement in HRQOL for the patient .Abbreviations .Dermatology Life Quality Index .", "label": "", "metadata": {}, "score": "72.06723"}
{"text": "This likely reflects improvements in painful psoriatic plaques and/or joint pain associated with comorbid PsA , although only a minority of patients reported the presence of arthritis .", "label": "", "metadata": {}, "score": "72.15811"}
{"text": "Conclusions : Application of EMLA?cream can be effectively incorporated as a routine pain- relieving intervention within routine vaccination appointments .Keywords Eutectic mixture of local anaesthetics ( EMLA ? ) , childhood vaccination , pain assessment , vaccination pain Date received : 22 September 2013 ; accepted : 28 September 2013 Journal of International Medical Research 2014 , Vol .", "label": "", "metadata": {}, "score": "72.68469"}
{"text": "Based on a Dermatologist 's Evalution of the Change in Subject 's Score of Target Treatment Areas [ Time Frame : baseline through Study Day 36 ( Visit 7 ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "73.03981"}
{"text": "The Clinical Effect of Low - Intensity Electromagnetic Field Neurostimulation in Fibromyalgia Syndrome Patients .Change in Tender Point Pain Threshold [ Time Frame : Total timeframe 13 weeks : baseline followed by 11 weeks of treatment with outcome assessed within 14 days following end of treatment ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "73.04892"}
{"text": "Change Form Baseline in O'Leary - Sant Interstitial Cystitis Symptom Index ( ICSI )Score [ Time Frame : Baseline , Days 7 , 14 , 28 and 42 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "73.06667"}
{"text": "Change From Baseline in mRSS at Week 48 [ Time Frame : Baseline , Week 48 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "73.067"}
{"text": "It is expected that as vaccination nurses become more familiar with the EMLA ? application procedures , the time to first vaccination will decrease further toward the hospital 's baseline measurement time of 47.34 ?", "label": "", "metadata": {}, "score": "73.067474"}
{"text": "Taddio et al.20reported a comparable mean?SD waiting time of 41.6 ?28.7min for childhood vaccination appointments in eight outpatient primary care clinics .This waiting time included the general waiting room time plus examination room time before the actual vaccine injection , without implementing any extra pain - relieving strat- egy .", "label": "", "metadata": {}, "score": "73.11351"}
{"text": "This FACIT - Fatigue Scale was a 13-item measure with participants scoring each item on a 5-point scale ( 0 to 4 ) up to 52 points .", "label": "", "metadata": {}, "score": "73.14071"}
{"text": "PubMed .Strand V , Bombardier C , Maetzel A , Scott D , Crawford B : Use of minimum clinically important differences ( MCID ) in evaluating patient responses to treatment of rheumatoid arthtitis ( RA ) [ abstract 810].", "label": "", "metadata": {}, "score": "73.21356"}
{"text": "Kurd SK , Gelfand JM : The prevalence of previously diagnosed and undiagnosed psoriasis in US adults : results from NHANES 2003 - 2004 .J Am Acad Dermatol 2009 , 60 : 218 - 224 .", "label": "", "metadata": {}, "score": "73.296524"}
{"text": "At baseline , mean SF-36 MCS scores across treatment groups were 0.5 SDs lower than US normative scores of 50 ( range : 45.7 - 47.0 ) , whereas SF-36 PCS scores approximated 50 ( range 48.6 - 49.3 ) .", "label": "", "metadata": {}, "score": "73.42419"}
{"text": "Mentions : Overall , the recurrence rate was 4 % in the GA group and 2.7 % in the LA group .The failure rate was 2 % in the GA group with none in the LA group .", "label": "", "metadata": {}, "score": "73.604126"}
{"text": "PubMed View Article .Basra MK , Fenech R , Gatt RM , Salek MS , Finlay AY : The Dermatology Life Quality Index 1994 - 2007 : a comprehensive review of validation data and clinical results .", "label": "", "metadata": {}, "score": "73.60767"}
{"text": "PubMed View Article .Meyer N , Paul C , Feneron D , Bardoulat I , Thiriet C , Camara C , Sid - Mohand D , Le Pen C , Ortonne JP : Psoriasis : an epidemiological evaluation of disease burden in 590 patients .", "label": "", "metadata": {}, "score": "73.617775"}
{"text": "It is used to characterize drug absorption .Mean Serum Concentrations of Interleukin ( IL)-6 by Visit [ Time Frame : Baseline , Weeks 1 , 2 , 3 , 8 , 16 , 24 , and 48 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "73.82924"}
{"text": "EMLA?Cream Package insert , AstraZeneca .Taddio A , Appleton M , Bortolussi R , et al .Reducing the pain of childhood vaccination : an evidence - based clinical practice guideline .", "label": "", "metadata": {}, "score": "73.99858"}
{"text": "Total crying time after the injection was significantly shorter in the EMLA?group compared with the placebo group ( 24.8 ?20.6s versus 43.3 ?Eight children ( 7.5 % ) in the EMLA?group cried severely to the extent of breath - holding , compared with 24 children ( 22.0 % ) in the placebo group ( P\u00bc0.003 ) .", "label": "", "metadata": {}, "score": "74.00159"}
{"text": "10.1136/ard.2009.115550 PubMed Central PubMed View Article .Ara R , Brazier J : Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference - based score from published studies ( where patient level data are not available ) .", "label": "", "metadata": {}, "score": "74.881744"}
{"text": "A reduction of at least 1.2 units in DAS28 was considered clinically significant improvement .Percentage of Participants Achieving LDA Assessed Using DAS28[ Time Frame : Weeks 4 , 8 , 12 , 16 , 20 , 24 , 36 , 48 and 52 ] [ Designated as safety issue : No ] . DAS28", "label": "", "metadata": {}, "score": "74.885025"}
{"text": "The tolerability findings are important in their relationship to the improved HRQOL seen in this study .While improvement in the severity of disease can be expected in most cases to improve HRQOL , there are some instances in which tolerability and safety issues may abrogate this benefit .", "label": "", "metadata": {}, "score": "75.130936"}
{"text": "Mean Serum Concentrations of Soluble IL-6 Receptor ( R ) by Visit [ Time Frame : Baseline , Weeks 1 , 2 , 3 , 8 , 16 , 24 , and 48 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "75.17447"}
{"text": "Gender .Both .Ages .18 Years and older .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects The purpose of this study is to determine whether persons treated with a low - intensity , noninvasive form of cortical electrical stimulation experience a reduction in symptoms of fibromyalgia different than persons receiving a sham treatment .", "label": "", "metadata": {}, "score": "75.18074"}
{"text": "Conclusions .Moderate to severe plaque psoriasis is associated with a negative impact on HRQOL , including pain and social and emotional functioning .Assessment of clinical signs and symptoms , as well as PROs , is useful in determining the impact of psoriasis and the clinical efficacy of treatment .", "label": "", "metadata": {}, "score": "75.186646"}
{"text": "However , LA is better than GA in our opinion .Figure 3 : Mean values of visual analog scale scores for back pain , leg pain , and Oswestry Disability Index results in the local anesthesia group .", "label": "", "metadata": {}, "score": "75.37879"}
{"text": "PRO assessments .The DLQI is a 10-item questionnaire that assesses the impact of skin disease on HRQOL over the previous week .SF-36 is a generic HRQOL questionnaire with 36 questions combined into 8 domains , scored from 0 ( worst ) to 100 ( best ) .", "label": "", "metadata": {}, "score": "75.44649"}
{"text": "Studies have focused on evaluating pain associated with specific vaccine types in a particular age group.14 - 16In contrast , the present study included all eligible children who presented to the Well - baby Paediatric Clinic forroutine Furthermore , the pain associated with all vaccine injections given to the children was assessed .", "label": "", "metadata": {}, "score": "75.681366"}
{"text": "Females who are planning a pregnancy , who are pregnant , or who are breastfeeding .Inability or unwillingness to discontinue current AD treatment(s ) .", "label": "", "metadata": {}, "score": "76.27536"}
{"text": "However , LA is better than GA in our opinion .To evaluate the effectiveness of topical eutectic mixture of local anaesthetics ( EMLA \u00ae ) cream in reducing the pain associated with vaccination injections .", "label": "", "metadata": {}, "score": "76.2847"}
{"text": "J Pain Symptom Manage 1995 ; 10 : 456 - 463 .Taddio A , Hogan ME , Moyer P , et al .Evaluation of the reliability , validity and practicality of 3 measures of acute pain in infants undergoing immunization injections .", "label": "", "metadata": {}, "score": "76.37541"}
{"text": "In addition , the mean total vaccination appointment time after administering the EMLA?cream did not differ markedly from the mean?SD waiting time at the King Khalid University Hospital , which was previously found to be 47.34 ?", "label": "", "metadata": {}, "score": "76.40143"}
{"text": "Consistent with findings from other studies [ 7 ] , psoriasis appears to have relatively greater impact on mental health rather than physical domains , as patients report larger decrements in RE and SF and to a lesser degree BP domains .", "label": "", "metadata": {}, "score": "76.439644"}
{"text": "PASI-75 : .SDs : .Standard deviations .SF : .Social Functioning .SF-36 : . 36-item Short - Form Health Survey .", "label": "", "metadata": {}, "score": "76.49754"}
{"text": "However , because the present study was conducted in a relatively small number of children from a single immunization . centre , these findings may warrant further research in this regard .", "label": "", "metadata": {}, "score": "76.54727"}
{"text": "The endpoint of the scale was pruritus .Each domain was scored on a 5-point scale , the scores of each of the five domains were achieved separately and then summed together to obtain a total 5-D score .", "label": "", "metadata": {}, "score": "76.63287"}
{"text": "PubMed .Kurd SK , Troxel AB , Crits - Christoph P , Gelfand JM : The risk of depression , anxiety , and suicidality in patients with psoriasis : a population - based cohort study .", "label": "", "metadata": {}, "score": "76.72869"}
{"text": "Application of EMLA \u00ae cream can be effectively incorporated as a routine pain - relieving intervention within routine vaccination appointments .Full - text .Research Report EMLA?cream : A pain - relieving strategy for childhood vaccination Manal Abuelkheir1 , Deema Alsourani2 , Ayman Al - Eyadhy3 , Mohamad - Hani Temsah3 , Sultan Ayoub Meo4and Fahad Alzamil3 Abstract Objectives : To evaluate the effectiveness of topical eutectic mixture of local anaesthetics ( EMLA ? ) cream in reducing the pain associated with vaccination injections .", "label": "", "metadata": {}, "score": "76.81952"}
{"text": "Additional results are anticipated .In addition , apremilast is currently being investigated in phase III clinical trials for the treatment of PsA and ankylosing spondylitis .", "label": "", "metadata": {}, "score": "77.01029"}
{"text": "10.1111/j.1365 - 2133.2005.06948.x PubMed View Article .Lebwohl M , Papp K , Han C , Schenkel B , Yeilding N , Wang Y , Krueger GG : Ustekinumab improves health - related quality of life in patients with moderate - to - severe psoriasis : results from the PHOENIX 1 trial .", "label": "", "metadata": {}, "score": "77.201355"}
{"text": "Known active current or history of recurrent infections .Use of any investigational , biologic , or immunosuppressive therapies including intra - articular or parenteral corticosteroids prior to study enrollment as specified in the protocol .", "label": "", "metadata": {}, "score": "77.2157"}
{"text": "Pain reduction during pediatric immunizations : evidence - based review and recommendations .Pediatrics 2007 ; 119 : e1184-e1198 .Taddio A , Chambers CT , Halperin SA , et al .", "label": "", "metadata": {}, "score": "77.25326"}
{"text": "Primary Purpose : Treatment .Official Title : .A Multicenter , Randomized , Double - Blind , Vehicle - Controlled Study of the Efficacy , Safety and Tolerability of TS-022 in Adult Patients With a Diagnosis of Atopic Dermatitis ( AD ) With Moderate to Very Severe Pruritus .", "label": "", "metadata": {}, "score": "77.259155"}
{"text": "Cassidy KL , Reid GJ , McGrath PJ , et al .A randomized double - blind , placebo - con- trolled trial of the EMLA patch for the reduction of pain associated with intramus- cular injection in four to six - year - old chil- dren .", "label": "", "metadata": {}, "score": "77.30391"}
{"text": "VS , CH , RMD , RMS , KAP : Analyzed and interpreted the data and helped to draft the manuscript .VS , DF , CH , RMD , RMS , KAP : All authors had full access to the data and have read and approved the final manuscript .", "label": "", "metadata": {}, "score": "77.68332"}
{"text": "10.1001/archdermatol.2010.186 PubMed Central PubMed .Strand V , Sharp V , Koenig AS , Park G , Shi Y , Wang B , Zack DJ , Fiorentino D : Comparison of health - related quality of life in rheumatoid arthritis , psoriatic arthritis and psoriasis and effects of etanercept treatment .", "label": "", "metadata": {}, "score": "77.69926"}
{"text": "The change in tender point pain threshold is determined by subtracting values at baseline from values at end of treatment .Thus a positive difference represents pain improvement ( i.e .. a better outcome ) .", "label": "", "metadata": {}, "score": "77.79364"}
{"text": "The left - hand extreme of the line equals 0 mm , and is described as \" no disease activity \" ( symptom - free and no arthritis symptoms ) and the right - hand extreme equals 100 mm , as \" maximum disease activity \" ( maximum arthritis disease activity ) .", "label": "", "metadata": {}, "score": "77.802155"}
{"text": "The left - hand extreme of the line equals 0 mm , and is described as \" no disease activity \" ( symptom - free and no arthritis symptoms ) and the right - hand extreme equals 100 mm , as \" maximum disease activity \" ( maximum arthritis disease activity ) .", "label": "", "metadata": {}, "score": "77.802155"}
{"text": "Uninvolved skin at injection sites .Negative pregnancy test for a female subject of childbearing potential .Exclusion Criteria : .Major surgery ( including joint surgery ) within 8 weeks prior to and/or during study enrollment .", "label": "", "metadata": {}, "score": "77.82898"}
{"text": "Participant reported symptom of bladder pain in the prior 24 hours using a 10 centimeter ( cm ) horizontal line Pain Visual Analog Scale recorded in a diary .", "label": "", "metadata": {}, "score": "78.1652"}
{"text": "Authors ' contributions .All authors had full access to all of the data in the study .VS , DF , CH , RMD , RMS , KAP : Conceived of the study , participated in the design and coordination of the study , and helped to draft the manuscript .", "label": "", "metadata": {}, "score": "78.36033"}
{"text": "10.1002/art.34627 PubMed View Article .Gottlieb AB , Strober B , Krueger JG , Rohane P , Zeldis JB , Hu CC , Kipnis C : An open - label , single - arm pilot study in patients with severe plaque - type psoriasis treated with an oral anti - inflammatory agent , apremilast .", "label": "", "metadata": {}, "score": "78.472824"}
{"text": "Page 3 . aged ? 1 year ) before vaccination .Note that no intervention was performed with regard to the time of application prior to vaccin- ation .", "label": "", "metadata": {}, "score": "78.49597"}
{"text": "A randomized controlled trial .Br J Dermatol 2008 , 158 : 116 - 121 .PubMed .Reich K : Apremilast , an oral phosphodiesterase 4 inhibitor , in patients with moderate to severe psoriasis : 16-week results of a phase 3 , randomized , controlled trial ( ESTEEM 1 ) [ oral presentation ] .", "label": "", "metadata": {}, "score": "78.507034"}
{"text": "Open Label , Multicenter , Trial to Evaluate Safety , Tolerability and Efficacy of Tocilizumab in Monotherapy or in Combination With MTX in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non Biologic DMARDs .", "label": "", "metadata": {}, "score": "78.56874"}
{"text": "Pharmacokinetics : Area under the concentration -- time curve ( AUC ) [ Designated as safety issue : No ] .Pharmacodynamics : sIL-6R / IL-6 levels [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "78.657745"}
{"text": "J Eur Acad Dermatol Venereol 2000 , 14 : 267 - 271 .10.1046/j.1468 - 3083.2000.00085.x PubMed View Article .Kimball AB , Gladman D , Gelfand JM , Gordon K , Horn EJ , Korman NJ , Korver G , Krueger GG , Strober BE , Lebwohl MG : National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening .", "label": "", "metadata": {}, "score": "78.86199"}
{"text": "Symptoms for at least 48 months with no recent remission of symptoms to any degree .Exclusion Criteria : .Developmental disabilities , or significant psychological disorder ( except depression and anxiety disorders ) for which treatment has become necessary .", "label": "", "metadata": {}, "score": "78.88156"}
{"text": "Device : Noninvasive cortical electrical stimulation .Subjects will receive 22 sessions of the intervention protocol , twice per week for a total of 11 weeks .", "label": "", "metadata": {}, "score": "79.07716"}
{"text": "The applied cream was covered with an occlusive dressing and the time of application was recorded .The child was subsequently enrolled in the normal routine process of paediatrician interview in the examination room followed by vaccination .", "label": "", "metadata": {}, "score": "79.16528"}
{"text": "The investigator assessed the urethra and bladder for the following : visibility of ureters , stricture , erythema , presence and number of Hunner 's lesion(s ) and the extent of erythema .", "label": "", "metadata": {}, "score": "79.2518"}
{"text": "No preview \u00b7 Article \u00b7 Dec 2009 \u00b7 Journal of the European Academy of Dermatology and Venereology Current Primary Outcome Measures ICMJE ( submitted : October 8 , 2015 ) .", "label": "", "metadata": {}, "score": "79.3423"}
{"text": "Biological : ESBA105 ophthalmic solution .Following Run - In , patients qualifying for treatment were randomized 2:1 to receive ESBA105 ( experimental group ) or Vehicle ( control group ) for 4 weeks .", "label": "", "metadata": {}, "score": "79.36864"}
{"text": "Zempsky WT .Pharmacologic approaches for reducing venous access pain in children .Pediatrics 2008 ; 122(suppl .3 ) : S140-S153 .Kikuta A , Gardezi F , Dubey V , et al .", "label": "", "metadata": {}, "score": "79.39606"}
{"text": "Paediatrics & Child Health Division , The Royal Australasian College of Physicians .Guideline statement : management of proce- dure - related pain in children and adolescents .", "label": "", "metadata": {}, "score": "79.4094"}
{"text": "There were no medical or infectious complications in either group .Conclusion : Disc herniation at the L5-S1 level can be adequately treated endoscopically with an interlaminar approach .", "label": "", "metadata": {}, "score": "79.49705"}
{"text": "There were no medical or infectious complications in either group .Conclusion : Disc herniation at the L5-S1 level can be adequately treated endoscopically with an interlaminar approach .", "label": "", "metadata": {}, "score": "79.49705"}
{"text": "The total vaccination appointment time was calculated from when the child arrived in the Well - baby Paediatric Clinic until the child received the first vaccine injection .", "label": "", "metadata": {}, "score": "80.0522"}
{"text": "10.1111/j.1524 - 4733.2008.00428.x PubMed View Article .Ware J , Kosinski M , Dewey JE : How to Score Version 2 of the SF-36 Health Survey .", "label": "", "metadata": {}, "score": "80.15521"}
{"text": "10.1136/ard.2007.072652 PubMed View Article .Richards HL , Fortune DG , Griffiths CE : Adherence to treatment in patients with psoriasis .J Eur Acad Dermatol Venereol 2006 , 20 : 370 - 379 .", "label": "", "metadata": {}, "score": "80.64027"}
{"text": "The total score indicated the participant 's self - assessed level of disability .The HAQ - DI was the sum of the domain scores , divided by the number of domains that have a score ( i.e. the average score ) , with total range of 0 to 3 , higher scores showing larger functional limitation .", "label": "", "metadata": {}, "score": "80.73424"}
{"text": "Central black horizontal lines represent the medians ; extremities of the boxes show upper and lowerquartiles of data ; error bars represent minimum and maximum values .", "label": "", "metadata": {}, "score": "81.06313"}
{"text": "A tender point is considered \" positive \" if less than 4 kilograms per centimeter squared pressure is required to elicit a painful response .The change in number of positive tender points is determined by subtracting the number of positive tender points at baseline from the number of positive tender points at end of treatment .", "label": "", "metadata": {}, "score": "81.53905"}
{"text": "Thus , a negative value represents sleep improvement ( i.e. a better outcome ) , while a positive value represents sleep worsening ( i.e. a worse outcome ) .", "label": "", "metadata": {}, "score": "81.555046"}
{"text": "The most frequently reported adverse events were headache , nausea , vomiting , nasopharyngitis , and upper respiratory tract infection .Gastrointestinal events were generally transient .", "label": "", "metadata": {}, "score": "81.60874"}
{"text": "The severity and extent of psoriasis and atopic dermatitis was assessed by their area and severity index .We measured nitrate as a metabolite of nitric oxide , malondialdehyde as a major lipid oxidation product , and 8-hydroxydeoxyguanosine ( 8-OHdG ) as a DNA oxidation marker .", "label": "", "metadata": {}, "score": "81.68763"}
{"text": "The range of dolorimeter values for each tender point site is 0 - 4 ( units are kilograms per square centimeter , i.e. kg / cm^2 ) .", "label": "", "metadata": {}, "score": "81.824165"}
{"text": "Kikuta A , Boon H , Shah V , et al .Survey of attitudes and practices of physicians and nurses regarding analgesia during routine childhood immunizations .", "label": "", "metadata": {}, "score": "82.008194"}
{"text": "Participants were instructed to to put a mark on the line at the point that best described their bladder pain with 0 ( far left on the line ) reflecting no pain and 10 ( far right on the line ) reflecting worse possible pain .", "label": "", "metadata": {}, "score": "82.02763"}
{"text": "Participants were instructed to to put a mark on the line at the point that best described their bladder pain with 0 ( far left on the line ) reflecting no pain and 10 ( far right on the line ) reflecting worse possible pain .", "label": "", "metadata": {}, "score": "82.02763"}
{"text": "Participants were instructed to to put a mark on the line at the point that best described their bladder pain with 0 ( far left on the line ) reflecting no pain and 10 ( far right on the line ) reflecting worse possible pain .", "label": "", "metadata": {}, "score": "82.02763"}
{"text": "Halperin BA , Halperin SA , McGrath P , et al .Use of lidocaine - prilocaine patch to decrease intramuscular injection pain does not adversely affect the antibody response to diphtheria - tetanus - acellular pertussis - inacti- vated poliovirus - Haemophilus influenza type b conjugate and hepatitis B vaccines in infants from birth to six months of age .", "label": "", "metadata": {}, "score": "82.24933"}
{"text": "Given the generally high level of emotional distress patients report regarding psoriasis symptoms , it is important to describe the potential impact of treatment on emotional functioning .", "label": "", "metadata": {}, "score": "82.30058"}
{"text": "A total of 216 children who received 564 vaccination injections ( median of three injections per child ) were randomly assigned to receive either EMLA ?", "label": "", "metadata": {}, "score": "82.44658"}
{"text": "Introduction Pain in children is underestimated globally and continues to be suboptimally mana- ged.1 - 3Currently , vaccine injections are considered to be source of iatrogenic pain in childhood.3,4 They are repeatedly administered to almost all children throughout infancy , childhood and adolescence .", "label": "", "metadata": {}, "score": "82.47273"}
{"text": "Background .Psoriasis is a chronic inflammatory disease that affects approximately 1 % to 3 % of the worldwide population [ 1 , 2 ] .", "label": "", "metadata": {}, "score": "82.50934"}
{"text": "In comparison , a similar group of subjects will receive the same treatment protocol without the actual stimulation signal being applied .The signal utilized is a modulated form that permits very low - intensity signals to pass through outer tissues with less attenuation due to tissue impedance .", "label": "", "metadata": {}, "score": "83.36928"}
{"text": "Allocation : Non - Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Single Group Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "83.40202"}
{"text": "An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason : death ; initial or prolonged inpatient hospitalization ; life - threatening experience ( immediate risk of dying ) ; persistent or significant disability / incapacity ; congenital anomaly .", "label": "", "metadata": {}, "score": "83.43301"}
{"text": "Evidence from other needle procedures showed no benefit of acetaminophen or ibuprofen .The administration of topical anesthetics before and breastfeeding during vaccine injections showed mixed results when compared to topical anesthetics alone .", "label": "", "metadata": {}, "score": "83.52748"}
{"text": "Change in physical function , assessed by Scleroderma Health Assessment Questionnaire - Disability Index ( SHAQ - DI ) [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "83.58283"}
{"text": "This multicenter , randomized , double - blind , placebo - controlled , two - arm , parallel - group study will evaluate the efficacy and safety of RoActemra/ Actemra ( tocilizumab ) in patients with systemic sclerosis .", "label": "", "metadata": {}, "score": "83.802"}
{"text": "10.1111/j.1365 - 2133.2009.09491.x PubMed View Article .Reich K , Nestle FO , Papp K , Ortonne JP , Evans R , Guzzo C , Li S , Dooley LT , Griffiths CE : Infliximab induction and maintenance therapy for moderate - to - severe psoriasis : a phase III , multicentre , double - blind trial .", "label": "", "metadata": {}, "score": "83.83317"}
{"text": "10.1016/S0140 - 6736(12)60642 - 4 PubMed View Article .Schett G , Wollenhaupt J , Papp K , Joos R , DeVlam KL , Rodrigues JF , Vessey A , Hu CC , Stevens R : Oral apremilast in the treatment of active psoriatic arthritis : results of a multicenter , randomized , double - blind , placebo - controlled study .", "label": "", "metadata": {}, "score": "83.88389"}
{"text": "Baumer W , Hoppmann J , Rundfeldt C , Kietzmann M : Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis .", "label": "", "metadata": {}, "score": "83.92221"}
{"text": "glucose- deficiency ; Study protocol Based on a computer - generated schedule , children were randomized at study entry to receive either ? 0.5 g EMLA ?", "label": "", "metadata": {}, "score": "83.94458"}
{"text": "The failure rate was 2 % in the GA group with none in the LA group .The success rate of surgery was 94 % in the GA group and 97.3 % in the LA group .", "label": "", "metadata": {}, "score": "84.07436"}
{"text": "Study design .This phase IIb RCT was conducted at 35 sites in the United States and Canada between September 2008 and November 2009 .Methods , including enrollment , study design , and procedures , have been previously published [ 20 ] .", "label": "", "metadata": {}, "score": "84.31326"}
{"text": "The left - hand extreme of the line equals 0 mm , and is described as \" no pain \" and the right - hand extreme equals 100 mm as \" unbearable pain \" .", "label": "", "metadata": {}, "score": "84.3578"}
{"text": "Thus , a negative value represents pain improvement ( i.e. a better outcome ) , while a positive value represents pain worsening ( i.e. a worse outcome ) .", "label": "", "metadata": {}, "score": "84.41922"}
{"text": "Current pregnancy , or plans to become pregnant during the study period .Any other condition deemed to pose a risk to the patient at the discretion of the investigators .", "label": "", "metadata": {}, "score": "84.48854"}
{"text": "The efficacy of apremilast , a phosphodiesterase-4 inhibitor , in the treatment of moderate to severe psoriasis : results of a phase 2 randomised study .", "label": "", "metadata": {}, "score": "84.49883"}
{"text": "This systematic review assessed the effectiveness and safety of pharmacotherapy and combined interventions for reducing vaccine injection pain in individuals across the lifespan .Electronic databases were searched for relevant randomized and quasi - randomized controlled trials .", "label": "", "metadata": {}, "score": "84.5569"}
{"text": "During the induction phase of the sequential topical therapy , both drugs were applied twice daily for a two to four - week period .During the following transitional phase , calcipotriol ointment alone was applied on weekdays , while both of these drugs were applied twice daily on weekends for an additional two to four weeks .", "label": "", "metadata": {}, "score": "84.874146"}
{"text": "Halperin SA , McGrath P , Smith B , et al .Lidocaine - prilocaine patch decreases the pain associated with the subcutaneous administration of measles - mumps - rubella vaccine but does not adversely affect the antibody response .", "label": "", "metadata": {}, "score": "85.021065"}
{"text": "Apremilast Dermatology Life Quality Index Phosphodiesterase 4 Psoriasis Quality of life SF-36 .Electronic supplementary material .The online version of this article ( doi : 10 .", "label": "", "metadata": {}, "score": "85.02164"}
{"text": "Current Secondary Outcome Measures ICMJE ( submitted : October 8 , 2015 ) .Change From Baseline in Physical Function Assessed by Scleroderma Health Assessment Questionnaire Disability Index ( SHAQ - DI )", "label": "", "metadata": {}, "score": "85.02961"}
{"text": "Division of Immunology and Rheumatology , Stanford University .Department of Dermatology , Stanford University School of Medicine .Celgene Corporation .Probity Medical Research .", "label": "", "metadata": {}, "score": "85.11404"}
{"text": "Skin thickening ( scleroderma ) limited to areas distal to the elbows or knees at screening .Previous treatment with tocilizumab .History of severe allergic or anaphylactic reactions to human , humanized , or murine monoclonal antibodies .", "label": "", "metadata": {}, "score": "85.26518"}
{"text": "The investigators propose that stimulation of cortical areas believed to be involved in dysfunctional sensory processing may have a beneficial influence on fibromyalgia symptoms .The aim of this randomized double blind , placebo controlled study is to evaluate the efficacy , safety , and tolerability of noninvasive cortical stimulation in the management of fibromyalgia symptoms .", "label": "", "metadata": {}, "score": "85.28401"}
{"text": "Houslay MD , Schafer P , Zhang KY : Keynote review : phosphodiesterase-4 as a therapeutic target .Drug Discov Today 2005 , 10 : 1503 - 1519 .", "label": "", "metadata": {}, "score": "85.320526"}
{"text": "Breastfeeding , topical anesthetics , sweet - tasting solutions and the combination of topical anesthetics and breastfeeding are effective in reducing vaccine injection pain in infants and children and its use should become the standard of care .", "label": "", "metadata": {}, "score": "85.40221"}
{"text": "The findings at Day 14 were compared to the findings at Baseline and were reported as Improvement , Worsening or No Change .Lidocaine Releasing Intravesical System ( LiRIS \u00ae ) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14 .", "label": "", "metadata": {}, "score": "85.63695"}
{"text": "ClinTher 2009 31(suppl . 2 ) : S152-S167 .Wright S , Yelland M , Heathcote K , et al .Fear of needles - nature and prevalence in general practice .", "label": "", "metadata": {}, "score": "85.71538"}
{"text": "The easiest and least invasive method to assess oxidative stress in patients may be the measurement of oxidation products in urine .This study aims to assess oxidative stress in psoriasis and atopic dermatitis patients .", "label": "", "metadata": {}, "score": "85.766136"}
{"text": "10.2340/00015555 - 0770 PubMed View Article .Kimball AB , Jacobson C , Weiss S , Vreeland MG , Wu Y : The psychosocial burden of psoriasis .", "label": "", "metadata": {}, "score": "85.81404"}
{"text": "10.1159/000275198 PubMed View Article .Ravindran V , Scott DL , Choy EH : A systematic review and meta - analysis of efficacy and toxicity of disease modifying anti - rheumatic drugs and biological agents for psoriatic arthritis .", "label": "", "metadata": {}, "score": "86.35172"}
{"text": "Authors ' original submitted files for images .Below are the links to the authors ' original submitted files for images .Competing interests .DF has served as an investigator for Amgen , Celgene Corporation , Janssen , Pfizer Inc , and Roche , and as a paid advisor for Amgen , Janssen , MedImmune , and Rigel .", "label": "", "metadata": {}, "score": "86.52225"}
{"text": "Concurrent skin pathology or recent history ( within the past 5 years ) of a chronic skin disease other than AD .Use of phototherapy , including exposure to tanning beds , within 28 days of Study Drug application .", "label": "", "metadata": {}, "score": "87.23772"}
{"text": "Expert Opin Investig Drugs 2012 , 21 : 261 - 264 .10.1517/13543784.2012.658915 PubMed View Article .Papp K , Cather J , Rosoph L , Sofen H , Langley RG , Matheson RT , Hu A , Day", "label": "", "metadata": {}, "score": "87.28099"}
{"text": "The endoscopic interlaminar approach can provide a direct pathway for decompression of disc herniation at the L5-S1 level .This study aimed to evaluate the clinical results of endoscopic interlaminar lumbar discectomy at the L5-S1 level and compare the technique feasibility , safety , and efficacy under local and general anesthesia ( LA and GA , respectively ) .", "label": "", "metadata": {}, "score": "87.37918"}
{"text": "The endoscopic interlaminar approach can provide a direct pathway for decompression of disc herniation at the L5-S1 level .This study aimed to evaluate the clinical results of endoscopic interlaminar lumbar discectomy at the L5-S1 level and compare the technique feasibility , safety , and efficacy under local and general anesthesia ( LA and GA , respectively ) .", "label": "", "metadata": {}, "score": "87.37918"}
{"text": "Augustin M , Reich K , Glaeske G , Schaefer I , Radtke M : Co - morbidity and age - related prevalence of psoriasis : analysis of health insurance data in Germany .", "label": "", "metadata": {}, "score": "87.52937"}
{"text": "The aim of this study is to characterize postburn itch in the pediatric population .This is a retrospective review from 2006 to 2013 for pediatric burn survivors who were enrolled in a longitudinal multicenter outcomes study .", "label": "", "metadata": {}, "score": "87.55625"}
{"text": "The two Abuelkheir et al.331 .Page 4 . groups were similar in age , sex and type of vaccine administered ( Table 1 ) .", "label": "", "metadata": {}, "score": "87.638885"}
{"text": "A Phase 2a Multicenter , Randomized , Double - Blinded , Placebo - Controlled Study Evaluating Safety , Tolerability and Efficacy of LiRIS \u00ae in Women With Interstitial Cystitis Followed by an Open Label Extension .", "label": "", "metadata": {}, "score": "87.694214"}
{"text": "Based on a Change in Score of Eruption in Proportionate Body Surface Areas [ Time Frame : baseline through Study Day 36 ( Visit 7 ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "87.80102"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Pruritus is a frequent and severe symptom and a significant cause of distress for adult burn patients .", "label": "", "metadata": {}, "score": "88.55365"}
{"text": "Official Title ICMJE .A PHASE II / III , MULTICENTER , RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS .", "label": "", "metadata": {}, "score": "88.80228"}
{"text": "All patients who complete part 1 of the study have the option to enter the extension .Choosing to participate in a study is an important personal decision .", "label": "", "metadata": {}, "score": "88.86368"}
{"text": "Joints on both sides of the body , including shoulders , elbows , wrists , 10 metacarpal phalangeal ( MCP ) joints , 10 proximal interphalangeal joint ( PIP ) joints , and both knees , were assessed .", "label": "", "metadata": {}, "score": "89.226425"}
{"text": "MacLean S , Obispo J and Young KD .The gap between pediatric emergency department Abuelkheir et al .335 .Page 8 .procedural pain management treatments available and actual practice .", "label": "", "metadata": {}, "score": "89.46489"}
{"text": "Serezani CH , Ballinger MN , Aronoff DM , Peters - Golden M : Cyclic AMP : master regulator of innate immune cell function .Am J Respir Cell Mol Biol 2008 , 39 : 127 - 132 .", "label": "", "metadata": {}, "score": "89.52494"}
{"text": "10.1016/S0140 - 6736(05)67566 - 6 PubMed View Article .Saurat JH , Guerin A , Yu AP , Latremouille - Viau D , Wu EQ , Gupta SR , Bao Y , Mulani PM : High prevalence of potential drug - drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis : associated clinical and economic outcomes in real - world practice .", "label": "", "metadata": {}, "score": "89.53735"}
{"text": "Itch was significantly correlated with associated symptoms .Regression analyses showed a correlation between itch intensity and pain at each time point .There was no association between itch intensity and burn etiology , age , gender , or burn size .", "label": "", "metadata": {}, "score": "90.02812"}
{"text": "10.1093/rheumatology / keq109 View Article .Leflunomide Rheumatoid Arthritis Investigators Group .Arthritis Rheum 2000 , 43 : 506 - 514 .CO;2-U PubMed View Article .", "label": "", "metadata": {}, "score": "90.48357"}
{"text": "Tocilizumab 8 mg / kg will be administered as an intravenous infusion every 4 weeks for a total of 6 infusions as monotherapy or in combination with methotrexate ( MTX ) .", "label": "", "metadata": {}, "score": "90.53584"}
{"text": "GA and LA are both effective for this procedure .Background : Open discectomy remains the standard method for treatment of lumbar disc herniation , but can traumatize spinal structure and leaves symptomatic epidural scarring in more than 10 % of cases .", "label": "", "metadata": {}, "score": "90.691986"}
{"text": "cream application as a routine pain - relieving the mostcommon fearin paediatric It is strategy appointments .duringchildhoodvaccination Patients and methods Study design and patient population The present study was a prospective , rando- mized , double - blind , analysis conducted Paediatric Clinic , King Khalid University Hospital , King Saud University , Riyadh , Saudi Arabia over a 1-week period during January 2012 .", "label": "", "metadata": {}, "score": "90.92449"}
{"text": "Background .Apremilast , a specific inhibitor of phosphodiesterase 4 , modulates pro - inflammatory and anti - inflammatory cytokine production .Objectives .Apremilast 's effect on patient - reported outcomes ( PROs ) in patients with moderate to severe psoriasis was evaluated in a phase IIb randomized , controlled trial ( NCT00773734 ) .", "label": "", "metadata": {}, "score": "91.295395"}
{"text": "Placebo Comparator : Placebo .Interventions : .Drug : Placebo .Drug : tocilizumab [ RoActemra/ Actemra ] .Experimental : Tocilizumab .Interventions : .", "label": "", "metadata": {}, "score": "91.57483"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT01254331", "label": "", "metadata": {}, "score": "92.04084"}
{"text": "Allocation : Randomized Endpoint Classification : Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Caregiver , Investigator , Outcomes Assessor ) Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "92.19091"}
{"text": "Shah V , Taddio A and Rieder MJ .Effectiveness and tolerability of pharmaco- logic and combined interventions for redu- cing injection pain during routine childhood immunizations : systematic review and meta- analyses .", "label": "", "metadata": {}, "score": "92.20989"}
{"text": "Eligibility Criteria ICMJE .Inclusion Criteria : .Systemic sclerosis , as defined by American College of Rheumatology ( 1980 ) criteria .Disease duration of .", "label": "", "metadata": {}, "score": "92.26726"}
{"text": "Patient understands the study procedures and agrees to participate in the study by giving written Informed Consent .Ability to read and understand English and to provide written informed consent and authorization for protected health information disclosure .", "label": "", "metadata": {}, "score": "92.43797"}
{"text": "Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Caregiver , Investigator , Outcomes Assessor ) Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "93.13226"}
{"text": "On the contrary , only urinary nitrate level was significantly higher in atopic dermatitis patients than those in healthy controls .The severity and extent of both psoriasis and atopic dermatitis significantly correlated with urinary nitrate level and malondialdehyde level , but it did not correlate with urinary 8-OHdG level .", "label": "", "metadata": {}, "score": "93.27649"}
{"text": "Above all , measurement of urinary nitrate may be most useful in the clinical assessment of oxidative stress in both psoriasis and atopic dermatitis patients .", "label": "", "metadata": {}, "score": "93.3369"}
{"text": "Cystitis Cystitis , Interstitial Urinary Bladder Diseases Urologic Diseases Lidocaine Anesthetics Anesthetics , Local Anti - Arrhythmia Agents Cardiovascular Agents Central Nervous System Agents .Central Nervous System Depressants Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Peripheral Nervous System Agents Pharmacologic Actions Physiological Effects of Drugs Sensory System Agents Sodium Channel Blockers Therapeutic Uses Voltage - Gated Sodium Channel Blockers The purpose of this study was to evaluate the efficacy of ESBA105 over vehicle in reducing the ocular symptoms of dry eye disease , as measured by a mean global Visual Analog Scale ( VAS ) discomfort score .", "label": "", "metadata": {}, "score": "93.62872"}
{"text": "National Immunization Programme , Basic Vaccination Schedule .Ministry of Health , Saudi Arabia . aspx ( accessed 7 December 2013 ) .Taddio A , Nulman I , Koren BS , et al .", "label": "", "metadata": {}, "score": "93.70393"}
{"text": "10.2174/187152807780077318 PubMed View Article .Br J Pharmacol 2010 , 159 : 842 - 855 .10.1111/j.1476 - 5381.2009.00559.x PubMed Central PubMed View Article .", "label": "", "metadata": {}, "score": "93.743164"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT00914186 The purpose of this study is to determine if LiRIS \u00ae , an investigational drug - delivery system , is safe , tolerable and effective in women with Interstitial Cystitis .", "label": "", "metadata": {}, "score": "93.88681"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT01338610 The study regimen consisted of 3 phases .", "label": "", "metadata": {}, "score": "94.0244"}
{"text": "Detailed Description : .There is increasing acceptance that pain in fibromyalgia is a result of dysfunctional sensory processing in the spinal cord and brain .", "label": "", "metadata": {}, "score": "94.21724"}
{"text": "Device : Sham treatment .Subjects in the placebo group will receive the exact same experience as those in the active treatment group .However , the device will not output any electrical stimulation signal .", "label": "", "metadata": {}, "score": "94.38937"}
{"text": "SF-36 domain scores at baseline and week 16 with apremilast 10 mg BID .Spydergram of SF-36 domain scores in patients receiving apremilast 10 mg BID versus US age-/gender - matched norms ( lavender ) and baseline ( dark blue ) .", "label": "", "metadata": {}, "score": "94.46903"}
{"text": "Sham Comparator : Cystoscopy Procedure .No intervention .Cystoscopy procedure is performed on study Day 0 and study Day 14 to mimick active and placebo study arms without insertion of Investigational Product into the bladder .", "label": "", "metadata": {}, "score": "94.5587"}
{"text": "This information will enable better tracking of outcomes and will serve as a baseline for assessing interventions .No preview \u00b7 Article \u00b7 Aug 2014 \u00b7 Journal of burn care & research : official publication of the American Burn Association .", "label": "", "metadata": {}, "score": "94.90358"}
{"text": "Exact protocol is set in software and is the same for all participants in the active treatment arm .Other Name : NeuroPoint .Placebo Comparator : Placebo group .", "label": "", "metadata": {}, "score": "95.277985"}
{"text": "Tasken K , Aandahl EM : Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 2004 , 84 : 137 - 167 .", "label": "", "metadata": {}, "score": "96.10562"}
{"text": "Clin J Pain 2012 ; 28 : 238 - 242 .336 Journal of International Medical Research 42(2 ) .Data provided are for informational purposes only .", "label": "", "metadata": {}, "score": "96.528244"}
{"text": "Adults , males or females , 18 - 65 years of age at the time of obtaining the written Informed Consent .Generally healthy subjects , who have no past or present history of any significant and/or newly - diagnosed disease or condition .", "label": "", "metadata": {}, "score": "96.67139"}
{"text": "To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .For general information , see Learn About Clinical Studies .", "label": "", "metadata": {}, "score": "96.928055"}
{"text": "Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .A Study of RoActemra/ Actemra ( Tocilizumab )", "label": "", "metadata": {}, "score": "96.95325"}
{"text": "SF-36 domain scores .At baseline , SF-36 domain scores were generally well matched between study groups and equaled or were within 10 points of age- and gender - matched normative scores .", "label": "", "metadata": {}, "score": "97.206604"}
{"text": "Background : Open discectomy remains the standard method for treatment of lumbar disc herniation , but can traumatize spinal structure and leaves symptomatic epidural scarring in more than 10 % of cases .", "label": "", "metadata": {}, "score": "97.24834"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT01180244 Publisher main menu .Follow BioMed Central .", "label": "", "metadata": {}, "score": "97.60934"}
{"text": "Other Names : .LiRIS \u00ae 400 mg .LiRIS \u00ae 400 mg ( Active ) .Placebo Comparator : LiRIS containing inactive substance only .", "label": "", "metadata": {}, "score": "97.73459"}
{"text": "As new therapies become available for managing psoriasis , it is important to evaluate their impact on patient - reported HRQOL .Research over the past decade in inflammatory diseases such as psoriasis has focused upon modulation of cyclic adenosine monophosphate ( cAMP ) , a naturally occurring intracellular secondary messenger that maintains immune homeostasis by modulating production of pro - inflammatory and anti - inflammatory cytokines [ 14 , 15 ] .", "label": "", "metadata": {}, "score": "98.47441"}
{"text": "10.1016/j.jaad.2008.01.006 PubMed Central PubMed View Article .Am J Clin Dermatol 2011 , 12 : 51 - 62 .10.2165/11530640 - 000000000 - 00000 PubMed View Article .", "label": "", "metadata": {}, "score": "99.32076"}
{"text": "Not Provided .Study Type ICMJE .Interventional .Study Phase .Phase 3 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Investigator )", "label": "", "metadata": {}, "score": "100.051056"}
{"text": "Cohen J : Statistical Power Analysis for the Behavioral Sciences . 2nd edition .Hillsdale , NJ : Lawrence Erlbaum Associates , Inc. ; 1988 .", "label": "", "metadata": {}, "score": "100.077194"}
{"text": "Drug : Lidocaine Releasing Intravesical System - LiRIS \u00ae .Lidocaine Releasing Intravesical System ( LiRIS \u00ae ) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14 .", "label": "", "metadata": {}, "score": "100.3465"}
{"text": "This is an open - access article distributed under the terms of the Creative Commons Attribution - Non Commercial - No Derivatives License 4.0 ( CCBY - NC - ND ) , where it is permissible to download and share the work provided it is properly cited .", "label": "", "metadata": {}, "score": "100.47222"}
{"text": "Drug : tocilizumab [ RoActemra/ Actemra ] .Not Provided .Completed .Enrollment ICMJE .Completion Date .June 2015 .Primary Completion Date .", "label": "", "metadata": {}, "score": "101.26449"}
{"text": "Other : LiRIS Placebo .LiRIS Placebo contains inactive substance only ; LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14 .", "label": "", "metadata": {}, "score": "101.49249"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : The involvement of oxidative stress in the pathogenesis of various skin disorders has been suggested for decades .", "label": "", "metadata": {}, "score": "101.94289"}
{"text": "Cystoscopy procedure only ; no investigational product is inserted / removed from the bladder .Other Names : .Sham Comparator .Sham arm .Detailed Description : .", "label": "", "metadata": {}, "score": "103.140915"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "104.334816"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "104.334816"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "104.334816"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "104.334816"}
{"text": "Can J Infect Dis Med Microbiol 2011 ; 22 : 43 - 48 .Taddio A , Hogan ME , Gerges S , et al .", "label": "", "metadata": {}, "score": "105.3061"}
{"text": "PDE4 inhibition elevates intracellular cAMP , which in turn down - regulates the inflammatory response [ 16 - 19 ] .Apremilast ( CC-10004 ; Celgene Corporation , Summit , NJ , USA ) is a small molecule that specifically inhibits PDE4 , thereby elevating intracellular cAMP levels .", "label": "", "metadata": {}, "score": "108.90155"}
{"text": "The study protocol was approved by the Ethical Review Board of the College of Medicine , King Saud University , Riyadh , Saudi Arabia .The parents / legal guardians of the children provided written informed consent for their participation in the study .", "label": "", "metadata": {}, "score": "114.78265"}
{"text": "We also extend our thanks to the nursing staff at the Well - baby Paediatric Clinic , King Khalid University Hospital , King Saud University , Riyadh , Saudi Arabia .", "label": "", "metadata": {}, "score": "120.22441"}
{"text": "Funding The authors are thankful to the Deanship of Scientific Research , King Riyadh , Saudi Arabia for supporting the work through a Research Group Project Grant ( RGP- VPP 181 ) .", "label": "", "metadata": {}, "score": "121.0346"}
{"text": "The impact factor represents a rough estimation of the journal 's impact factor and does not reflect the actual current impact factor .Publisher conditions are provided by RoMEO .", "label": "", "metadata": {}, "score": "129.33841"}
